Romidepsin
Graft Failure
Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
10 Active assets in the Graft Failure cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
TACROLIMUS Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Plerixafor Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
View all 10 →
Same molecule, other indications
Romidepsin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →